Xcout Intel
MannKind Corporation
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Subscribe to see MannKind Corporation’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
MannKind Corporation at a glance
MannKind Corporation is a biotechnology company headquartered in Danbury, United States. It is publicly listed (MNKD) with a market capitalisation of $1.1B. Xcout tracks 19 named people at MannKind Corporation, including Michael E. Castagna (Chief Executive Officer & Director).
MannKind Corporation leadership
- Michael E. CastagnaChief Executive Officer & Director
- Michael CastagnaChief Executive Officer
- Dominic MarascoPresident of Endocrine Business Unit
- Christopher PrentissChief Financial Officer
- Chris PrentissChief Financial Officer
- Stuart A. TrossChief People & Workplace Officer
13 more named people on record for MannKind Corporation, with roles, board committees and tenure — see the full roster →
Get MannKind Corporation's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on MannKind Corporation in Xcout Intel
- 19 named people with titles, LinkedIn and board committees
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access